Caris Life Sciences Inc (CAI)

Currency in USD
17.58
-0.96(-5.18%)
Closed·
17.92+0.34(+1.93%)
·
CAI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.2718.42
52 wk Range
14.1936.50
Key Statistics
Prev. Close
17.58
Open
18.16
Day's Range
17.27-18.42
52 wk Range
14.19-36.5
Volume
4.57M
Average Volume (3m)
4.64M
1-Year Change
-27.0237%
Book Value / Share
2.26
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CAI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.23
Upside
+94.71%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Caris Life Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

10 Buy
4 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 34.23
(+94.71% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Hold25.00+42.21%22.00Maintain10-11-2026
Baird
Buy33.00+87.71%32.00Maintain05-11-2026
BTIG
Buy38.00+116.15%-Maintain05-11-2026
TD Cowen
Buy38.00+116.15%36.00Maintain05-11-2026
BTIG
Buy38.00+116.15%33.00Maintain27-10-2026

Caris Life Sciences Inc Earnings Call Summary for Q2/2026

  • Q2 revenue hit $263.7M, beating estimates by 10.8%; shares surged 15.56% after-hours on strong clinical volume and pricing power.
  • Full-year revenue guidance raised to $1.03B-$1.04B from $1.00B-$1.02B; adjusted EBITDA of $55.7M marks fifth consecutive positive quarter.
  • Clinical cases reached record 59,200, up 18% YoY; gross margin expanded to 68% from 63% prior year on improved operating leverage.
  • Caris Detect multi-cancer test launched in June with strong demand; company tripling capacity from $1B to $3B annual revenue potential.
  • Q3 pricing guidance set at $3,800-$3,900 per test; MRD products and MI Clarity V2 expected to launch in second half of 2026.
Last Updated: 06-08-2026, 03:38 am
Read Full Transcript

Earnings

Latest Release
04-11-2026
EPS / Forecast
0.05 / 0.16
Revenue / Forecast
275.4M / --
EPS Revisions
Last 90 days

CAI Income Statement

Compare CAI to Peers and Sector

Metrics to compare
CAI
Peers
Sector
Relationship
P/E Ratio
52.5x−3.2x−0.2x
PEG Ratio
0.50−0.060.00
Price/Book
7.9x5.4x2.6x
Price / LTM Sales
4.8x5.9x2.6x
Upside (Analyst Target)
94.7%37.7%76.9%
Fair Value Upside
Unlock−6.9%14.9%Unlock

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
78.09M27.23%1.37B
Other Institutional Investors
105.22M36.69%1.85B
Public Companies & Retail Investors
103.48M36.08%1.82B
Total
286.78M100.00%5.04B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC13.37%3,83,30,6126,73,852
Whitney VI, L.P.3.93%1,12,56,6151,97,891

FAQ

What Is the Caris Life Sciences (CAI) Share Price Today?

The Caris Life Sciences share price today is 17.58.

What is the current Caris Life Sciences (CAI) share price and day range?

As of 21-11-2026, the Caris Life Sciences share price is 17.58, with a previous close of 17.58. The share price has ranged from 17.27 to 18.42 today, while the 52-week range spans from 14.19 to 36.50.

What Is the Caris Life Sciences Market Cap?

As of today, Caris Life Sciences market cap is 5.32B.

What Is the Caris Life Sciences (CAI) Share Price Target?

The average 12-month share price target for Caris Life Sciences is 34.23, with a high estimate of 38 and a low estimate of 25. 10 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +94.71% Upside potential.

What Is Caris Life Sciences's Earnings Per Share (TTM)?

The Caris Life Sciences EPS (TTM) is 0.34.

From a Technical Analysis Perspective, Is CAI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Caris Life Sciences Trade On?

Caris Life Sciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Caris Life Sciences?

The stock symbol for Caris Life Sciences is "CAI."

How Many Times Has Caris Life Sciences Stock Split?

Caris Life Sciences has split 0 times.

How Many Employees Does Caris Life Sciences Have?

Caris Life Sciences has 1846 employees.

What Is the CAI Premarket Price?

CAI's last pre-market stock price is 18.20. The pre-market share volume is 52,270.00, and the stock has changed by -0.34, or -1.83%.

What Is the CAI After Hours Price?

CAI's last after hours stock price is 17.92, the stock has changed by 0.34, or 1.93%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.